Peptic Ulcer - Pipeline Review, H2 2011
Global Markets Direct’s, 'Peptic Ulcer - Pipeline Review, H2 2011', provides an overview of the Peptic Ulcer therapeutic pipeline. This report provides information on the therapeutic development for Peptic Ulcer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Peptic Ulcer. 'Peptic Ulcer - Pipeline Review, H2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
- A snapshot of the global therapeutic scenario for Peptic Ulcer.
- A review of the Peptic Ulcer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Peptic Ulcer pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Peptic Ulcer.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage
Peptic Ulcer – Pipeline Review, H2 2011 Peptic Ulcer - Pipeline Review, H2 2011 Reference Code: GMDHC1277IDB Publication Date: August 2011 Peptic Ulcer – Pipeline Review, H2 2011 GMDHC1277IDB / Pub August 2011 © Global Markets Direct. This report is a licensed product and is not to be photocopied Page(1) Peptic Ulcer – Pipeline Review, H2 2011 Ta b le o f Co n te n ts Table of Contents 2 List of Tables 4 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Peptic Ulcer Overview 7 Therapeutics Development 8 An Overview of Pipeline Products for Peptic Ulcer 8 Peptic Ulcer Therapeutics under Development by Companies 10 Peptic Ulcer Therapeutics under Investigation by Universities/Institutes 12 Late Stage Products 13 Comparative Analysis 13 Mid Clinical Stage Products 14 Comparative Analysis 14 Early Clinical Stage Products 15 Comparative Analysis 15 Pre-Clinical Stage Products 16 Comparative Analysis 16 Peptic Ulcer Therapeutics - Products under Development by Companies 17 Peptic Ulcer Therapeutics - Products under Investigation by Universities/Institutes 18 Companies Involved in Peptic Ulcer Therapeutics Development 19 Allergan, Inc. 19 Sequella, Inc. 19 AstraZeneca PLC 20 Takeda Pharmaceutical Company Limited 20 aRigen Pharmaceuticals, Inc. 21 Vecta Ltd. 21 Medigreen Biotechnology Corporation 22 Peptic Ulcer - Therapeutics Assessment 23 Assessment by Monotherapy Products 23 Assessment by Combination Products 24 Assessment by Route of Administration 25 Assessment by Molecule Type 27 Drug Profiles 29 TAK-438 - Drug Profile 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 Nexium - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 SQ 109 - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 ARH-1029 - Drug Profile 32 Peptic Ulcer – Pipeline Review, H2 2011 GMDHC1277IDB / Pub August 2011 © Global Markets Direct. This report is a licensed product and is not to be photocopied Page(2) Peptic Ulcer – Pipeline Review, H2 2011 Product Description 32 Mechanism of Action 32 R&D Progress 32 Vecam - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 Nexium + Aspirin - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 Rabeprazole - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 Esomeprazole - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 AGN 201904 - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 Lansoprazole - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 MIC-31 - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 Peptic Ulcer Therapeutics – Drug Profile Updates 40 Peptic Ulcer Therapeutics - Discontinued Products 42 Peptic Ulcer - Featured News 43 Jul 01, 2011: AstraZeneca's NEXIUM Receives First Regulatory Approval In Japan For Treatment Of Acid-related Diseases 43 Appendix 44 Methodology 44 Coverage 44 Secondary Research 44 Primary Research 44 Expert Panel Validatio
Pages to are hidden for
"Peptic Ulcer - Pipeline Review, H2 2011"Please download to view full document